Immix Biopharma, Inc. Common Stock

IMMXNASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
11.92 USD
↘ 0.22 (1.81%)AT CLOSE (11:59 AM EDT)
12.07
↗ 0.15 (1.29%)
POST MARKET (AS OF 04:24 PM EDT)
Post Market
AS OF 04:24 PM EDT
12.07
↗ 0.15 (1.29%)
🟢Market: OPEN

IMMX is currently priced at $12.07. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics place IMMX at a fair price relative to peers.

Technical & fundamental data as of Sep 15, 2026.

Open?$12.28
High?$12.46
Low?$11.75
Prev. Close?$12.14
Volume?1.4M
Avg. Volume?1.5M
VWAP?$12.17
Rel. Volume?0.97x
Bid / Ask
Bid?$10.23 × 100
Ask?$14.30 × 100
Spread?$4.07
Midpoint?$12.27
Valuation & Ratios
Market Cap?868.5M
Shares Out?71.5M
Float?47.6M
Float %?66.6%
P/E Ratio?N/A
P/B Ratio?3.79
EPS?-$0.56
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
21
Market Cap
868.5M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.immixbio.com
Listed
2021-12-16
Address
11400 WEST OLYMPIC BLVD.
LOS ANGELES, CA 90064
Phone: (888) 958-1084
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
56
Piotroski F-Score?0/9Weak
Altman Z-Score?50.94Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.18%Squeeze Risk
Short Interest?9.6M
Days to Cover?5.9
Free Float47.6M
Avg Daily Volume1.6M
Settlement Date2026-08-31
Financial Health
Current Ratio?25.13Strong
Quick Ratio?25.13Strong
Cash Ratio?24.24Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
46
3.79FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-15.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
8
-17.4%WEAK▾
ROA?
S&P
3
-16.7%WEAK▾
Cash Flow & Enterprise
FCF?$-39089192
Enterprise Value?$643.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist